SOURCE: Paragon Financial Limited

Paragon Financial Limited

January 25, 2012 08:20 ET

Inovio Pharmaceuticals and Keryx Biopharmaceuticals Benefit From Strengthening Biotech Sector

The Paragon Report Provides Equity Research on Inovio Pharmaceuticals & Keryx Biopharmaceuticals

NEW YORK, NY--(Marketwire - Jan 25, 2012) - The biotechnology industry has performed well in the early stages of 2012. The iShares NASDAQ Biotechnology Index is presently up nearly eight percent month-on-month as the industry continues to recover nicely from the global economic crisis. According to a recent report from Global Industry Analysts, Inc. (GIA) the improving economic conditions have led to an increase in funding for the biotechnology industry. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Access to the full company reports can be found at:

GIA predicts the Global Biotechnology Market to Surpass US$320 Billion by 2015, as increased availability of funding for R&D, expanding use of biotechnology in agriculture and medical sciences, and favorable government initiatives are expected to drive growth in the biotechnology industry.

GIA argues that developing markets, especially India and China, will emerge as major agricultural and industrial biotechnology markets owing to rapid increase in population and income levels. "The two countries are emerging as key markets for biotech drugs due to their rich talent pool and low cost of investment," GIA stated in a press release.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Inovio Biomedical Corporation is focused on developing multiple DNA-based immunotherapies. The Company develops applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio is advancing its universal influenza vaccine strategy with a second Phase I influenza vaccine study.

Keryx Biopharmaceuticals, Inc., together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at